Solid pharmaceutical compositions containing benzofuran derivatives
AssigneeSanofi
InventorsBernard ABRAMOVICI, Jean-Claude GAUTIER, Jean-Claude GROMENIL, Jean-Marie MARRIER
Life of this patent
Estimating the term…
Abstract
The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.
Claims13
A solid pharmaceutical composition for oral administration comprising dronedarone, or a pharmaceutically acceptable salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients, wherein said pharmaceutical composition has a pharmacokinetic profile wherein the maximum plasmatic concentration of active principle following a single oral administration in a non-fasted human is less than about five times the maximum concentration of active principle following a single oral administration in a fasted human.
A solid pharmaceutical composition for oral administration comprising dronedarone, or a pharmaceutically acceptable salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients, wherein said pharmaceutical composition exhibits a mean AUC of the active principle following a single oral administration in a non-fasted human which is less than about five times the mean AUC of the active principle following a single oral administration of the pharmaceutical composition in a fasted human.
A solid pharmaceutical composition for oral administration comprising 200 to 400 mg of dronedarone hydrochloride, calculated in base form, and poloxamer 407, optionally in combination with one or more pharmaceutical excipients.
A method of treating a patient comprising orally administering a solid pharmaceutical composition comprising dronedarone, or a pharmaceutically acceptable salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients, wherein the bioavailability of the composition following a single oral administration in the not fasted state is less than about five times the bioavailability of the composition following a single oral administration in the fasted state.
Dependencies are inferred from the claim text.